What is KLOW used for?

KLOW is supplied strictly for in-vitro and laboratory research, not for human consumption. It is not an approved medicine. No study has tested the KLOW four-peptide combination itself; the evidence base is on the individual peptides.

Does PeptidesDirect publish the milligram amount of each peptide in the 80 mg KLOW blend?

Yes. KLOW is labeled as 50 mg GHK-Cu, 10 mg BPC-157, 10 mg full-length thymosin beta-4 (sold as TB-500) and 10 mg KPV, a nominal 80 mg total. That is the label recipe, not an exact measured content: the manufacturer-supplied batch report shows measured content that can differ from the label, so read the actual values on the certificate rather than assuming the vial matches 80 mg exactly.

Who tests KLOW batches, and is it independent?

The current KLOW Pink Cap batch has one manufacturer-supplied Janoshik report. PeptidesDirect did not commission or independently retest it, and KLOW is not among the products for which the shop commissioned a Liquilabs report. The report shows one 99.00% purity result and displayed content results of 44.34 mg GHK-Cu, 10.11 mg TB-500 and 10.84 mg BPC-157; KPV is omitted from the displayed content result. These results apply only to the reported batch. The certificate is listed at /coa.

How can a researcher verify the certificate of analysis for a specific KLOW batch?

Match the lot number printed on the vial to the lot number on the certificate, check which laboratory issued it and whether it was manufacturer-supplied or community-submitted, and read the fields actually reported (identity, content, and any purity result shown) rather than assuming a fixed set. Where the lab offers a verification link or code, cross-check the report against its own records.

Has the specific four-peptide KLOW combination been tested together for safety or interactions?

No. There is no published study of the four-peptide combination for efficacy, safety or interactions. The available data come from research on each peptide individually, so the blend should be treated as its own experimental variable rather than assumed to behave like the sum of the single-peptide literature.

How does the four-peptide KLOW blend differ from a two-peptide BPC-157/TB-500 combination or the GLOW blend?

KLOW adds GHK-Cu and KPV to BPC-157 and TB-500, and compared with the GLOW blend (GHK-Cu, BPC-157, TB-500) it additionally contains KPV, an anti-inflammatory tripeptide. These are compositional differences; no head-to-head study has compared the blends, so a difference in composition should not be presented as evidence of a different biological effect.

Which molecule is the TB-500 component in KLOW?

KLOW is labeled as containing full-length thymosin beta-4, the 43-amino-acid molecule rather than the short Ac-LKKTETQ fragment sometimes sold as TB-500. The manufacturer-supplied report lists a TB-500 content result, but the report and label do not establish that findings from other full-length thymosin beta-4 formulations transfer directly to the KLOW blend.

Is there published human data on BPC-157?

BPC-157 evidence is overwhelmingly preclinical, with only very limited human data. It is a synthetic peptide described as a fragment of a reported gastric protein, studied mainly in rodent injury models (Sikiric et al.). It does not have EU marketing authorisation and is not FDA-approved.

What clinical evidence exists for thymosin beta-4 (TB-500)?

Full-length thymosin beta-4 has been investigated in some early-phase (phase I and phase II) human trials, including topical and ophthalmic formulations, so it is not purely preclinical. Those trials used clinical-grade formulations and specific routes that do not establish the safety of this research material or of the KLOW blend, and it holds no EU marketing authorisation.

Are there safety signals for thymosin beta-4 that researchers should know about?

One in-vitro study added thymosin beta-4 at 0.1 or 1 mM to citrated whole blood from three porcine donor animals and reported reduced FIBTEM clot firmness when platelet function was inhibited. The authors said this might be relevant alongside antiplatelet medication, but the concentrations were far above normal plasma levels and the clinical significance is unknown. This was not a human safety finding, and no controlled human safety data exist for KLOW.

Are BPC-157, TB-500, GHK-Cu or KPV approved medicines in the EU?

No. None of the four components holds an EU marketing authorisation as a medicinal product, so KLOW cannot be marketed as a medicine. It is sold strictly as a research chemical for laboratory use; classification and sale requirements are jurisdiction-specific, and researchers should confirm the rules that apply in their own country.

Are any of the peptides in KLOW prohibited for athletes?

Yes, in general. Under the World Anti-Doping Agency Prohibited List, BPC-157 falls under S0 (non-approved substances) and thymosin beta-4 and its derivatives under S2.3, both prohibited at all times. That is a sport-specific classification, separate from KLOW's status as a research-only product not intended for any human use.

What doses were used in research on KLOW's components?

No dosing study exists for the KLOW combination and no controlled human protocol has been published for it. Rodent BPC-157 studies (Sikiric et al.) used nanogram-to-microgram-per-kilogram ranges. Published topical GHK-Cu studies used formulation-specific concentrations, while systemic dosing is not standardised. Self-reported community protocols circulate milligram-range figures for products sold as TB-500 and low-hundreds-of-micrograms subcutaneous figures for KPV; these are unvalidated, and the molecular identity of community products described as TB-500 is often undocumented, so those figures cannot be assigned confidently to full-length thymosin beta-4 or to KLOW. Per-peptide figures do not convert into a protocol for the blend and are not a recommendation.

What is needed to reconstitute KLOW for laboratory use?

Add a validated solvent slowly down the vial wall, not directly onto the powder, and mix by gentle swirling rather than vigorous shaking. A syringe is used only as a laboratory measuring tool to add solvent and withdraw aliquots for research, not for injection into a person or animal. Follow the specific product's documentation for the solvent and concentration rather than a single universal recipe, and note there is no validated fixed post-reconstitution shelf life.

Are GHK-Cu, KPV, BPC-157 and TB-500 available separately from the KLOW blend?

Yes. PeptidesDirect stocks these peptides as standalone research vials as well as in the KLOW blend, which suits protocols that need a single peptide, a different ratio, or to manage one component's supply independently. The blend suits protocols that want the four pre-weighed together; the choice depends on the research design.

Buy KLOW for Research: Composition and Evidence Limits

Q: What is the mechanistic basis for including KPV, and how does it compare to alpha-MSH?

KPV (Lys-Pro-Val) is an alpha-MSH-derived tripeptide studied for anti-inflammatory effects. Dalmasso et al. (2008) reported PepT1-mediated uptake, reduced NF-kB and MAP-kinase activation in stimulated human intestinal epithelial and T-cell lines, and reduced inflammatory endpoints after oral KPV in mouse colitis models. Luger et al. (2003) reviewed preclinical immunomodulatory findings for alpha-MSH and KPV, but did not establish that KPV is superior to alpha-MSH or effective in humans. These are preclinical findings, not established clinical effects.

Peptide research has evolved in recent years from studying individual peptides to exploring synergistic combinations. KLOW is one such combination: a blend of four peptides each studied in regeneration research: BPC-157, TB-500, GHK-Cu and KPV. Each is associated with a different phase of tissue repair in the individual literature, but the four-peptide combination itself has not been studied, so any complementary or synergistic behaviour is a hypothesis, not an established result.

KLOWregeneration

4-in-1 anti-aging peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg. Targets collagen synthesis, tissue regeneration, skin repair, and anti-inflammatory pathways.

For researchers looking to source KLOW in research-grade quality, the key questions are: What exactly does it contain, why this particular combination, and what should you look for when purchasing?

What Is KLOW?

KLOW is labeled as a four-peptide blend with a nominal total of 80 mg: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg full-length thymosin beta-4 (TB-500) and 10 mg KPV. Its four components are:

BPC-157 (Body Protection Compound-157): A synthetic 15-amino-acid peptide described in the literature as a fragment of a reported gastric protein. It has been studied predominantly in preclinical models of tendon, muscle and tissue repair.
TB-500 (full-length thymosin beta-4): KLOW is labeled as containing the full-length, 43-amino-acid thymosin beta-4 molecule rather than the short Ac-LKKTETQ fragment sometimes sold as TB-500. The manufacturer-supplied report lists a TB-500 content result. Full-length thymosin beta-4 literature is therefore the relevant molecular background, but formulation, route and blend differences mean that its findings do not apply directly to the supplied KLOW material.
GHK-Cu (Glycyl-L-histidyl-L-lysine-Copper): A copper complex of the tripeptide GHK. GHK itself occurs naturally and reported plasma levels decline with age (those measurements concern GHK, not the finished GHK-Cu material). GHK-Cu has been studied for effects on collagen-related gene expression and skin biology.
KPV (Lys-Pro-Val): An anti-inflammatory tripeptide derived from alpha-MSH (alpha-melanocyte-stimulating hormone). Dalmasso et al. (2008, Gastroenterology) reported PepT1-mediated KPV uptake in cell experiments and reduced inflammatory endpoints after oral KPV in mouse colitis models. These findings do not establish a human effect.

Why Is This Combination Being Researched?

The proposed rationale for KLOW maps the four components onto different stages studied in tissue-repair research, based on separate cell and animal literature; this mapping has not been validated for the blend:

Phase 1 - Inflammation Control: Luger et al. (2003, Annals of the New York Academy of Sciences) reviewed cell and mouse studies in which alpha-MSH or KPV modulated antigen-presenting-cell and contact-hypersensitivity endpoints; it did not establish that KPV is more potent than alpha-MSH or effective in humans. Dalmasso et al. (2008, Gastroenterology) reported PepT1-mediated KPV uptake, reduced NF-kB/MAPK activation and reduced IL-8 secretion in stimulated cultured intestinal epithelial and T-cell lines, plus reduced inflammatory endpoints after oral KPV in mouse colitis models. In separate preclinical models, BPC-157 altered some inflammatory endpoints; a direct BPC-157-driven JAK2/STAT3 anti-inflammatory pathway has not been established.

Phase 2 - Cell Migration and Angiogenesis: In cultured endothelial cells and vascular-sprouting assays, full-length thymosin beta-4 increased cell-migration and angiogenesis-related endpoints; these experiments do not establish an effect for the supplied KLOW material or in humans. In a rat alkali-burn model and cultured human endothelial cells, BPC-157 increased VEGF-A expression and angiogenesis-related endpoints; those experiments did not establish EGF upregulation or a human repair effect.

Phase 3 - Matrix Remodelling: Cultured-fibroblast studies have reported increased collagen synthesis after GHK-Cu exposure. A narrative review by Pickart and Margolina (2018, International Journal of Molecular Sciences) also summarises elastin-, glycosaminoglycan- and gene-expression findings from heterogeneous preclinical studies, including analyses using GHK in cultured cell lines; these results do not establish matrix remodelling by the supplied GHK-Cu component or KLOW in humans.

Overview of Mechanisms of Action

The individual-peptide literature reports pathways that could be complementary, but complementary activity has not been demonstrated for the KLOW blend:

NO Modulation: Preclinical studies report context-dependent interactions between BPC-157 and nitric oxide signalling; a defined mechanism and targeted increase in blood flow at a repair site have not been established in humans.
NF-kB Signalling: In stimulated cultured intestinal epithelial and T-cell lines, KPV reduced NF-kB activation; this does not establish a human clinical effect.
Actin Regulation: Full-length thymosin beta-4 binds and sequesters G-actin. Separate cell and vascular-sprouting studies link thymosin beta-4/actin dynamics to migration-related endpoints, but this does not establish tissue reorganisation by the KLOW blend.
GHK Gene-Expression Profiling: The profiling summarized by Pickart and Margolina used GHK in cultured cell lines. It does not establish that the finished GHK-Cu material activates wound-healing genes through a copper-dependent pathway in vivo.

These are pathways reported SEPARATELY for the individual peptides. The four-peptide combination itself has not been tested, so any complementary or synergistic behaviour is a hypothesis, not a demonstrated result.

Quality Criteria When Buying KLOW

For a multi-peptide blend like KLOW, quality control is even more important than for individual peptides. Researchers should look for the following:

Which lab, and what was tested: The current KLOW Pink Cap batch has one manufacturer-supplied Janoshik report; PeptidesDirect did not commission or independently retest it. The report shows one purity result of 99.00% and displayed content results of 44.34 mg GHK-Cu, 10.11 mg TB-500 and 10.84 mg BPC-157. KPV is omitted from the displayed content result. These are report-specific results, not a purity or content guarantee for other batches. The certificate is listed on our lab-reports page at /coa.

Per-component identity and content: For a four-peptide blend it is more informative to see identity and content reported per component than a single combined figure. Check the reported values on the batch certificate rather than assuming a fixed purity percentage for each component.

Labeled composition: KLOW is labeled as 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV; check the reported content against that label rather than assuming an exact measured ratio.

Dose Figures in the Research Literature

No dosing study exists for the KLOW combination, and no controlled human protocol has been published for it. The figures below are references from the individual-peptide literature or from self-reported community practice, not a dosage recommendation:

BPC-157: rodent studies (Sikiric et al.) administered it across a wide range, commonly reported around nanogram-to-microgram-per-kg levels. Community research protocols circulate low-microgram-to-few-hundred-microgram subcutaneous ranges; these are self-reported and unvalidated.
Products sold as TB-500: community protocols circulate milligram-range figures (often cited around a few milligrams initially, then lower); these are self-reported and unvalidated, and the molecular identity of products described as "TB-500" is often not documented, so the figures cannot be assigned confidently to full-length thymosin beta-4 or to KLOW.
GHK-Cu: Published topical GHK-Cu studies used formulation-specific concentrations; systemic dosing is not standardised.
KPV: Dalmasso et al. used oral administration in mouse colitis models; community subcutaneous ranges (low hundreds of micrograms) are self-reported and unvalidated.

These are per-peptide study or community figures. No controlled human dosing protocol exists for the KLOW combination, and these figures do not convert into one.

Storage and Handling

KLOW is supplied as a lyophilised powder; no blend-specific stability study is cited here, so use the supplier's documented storage conditions:

Before reconstitution: Follow the supplier's documented storage for the unopened lyophilised material, kept cold and protected from light and moisture.
After reconstitution: There is no single validated post-reconstitution shelf life for this blend, and it depends on the diluent and handling; treat a reconstituted vial as a short-lived working solution, keep it cold, and rely on the specific product's stability data and your own contamination controls rather than a fixed number of weeks.
Reconstitution: Add a validated solvent slowly down the vial wall, not directly onto the powder, and mix by gentle swirling rather than vigorous shaking.
Light protection: As a copper-containing blend (GHK-Cu), protection from light is applied as a precautionary storage condition; use amber or foil-wrapped vials.

Why Buy KLOW from PeptidesDirect?

For researchers in the EU, PeptidesDirect offers several advantages:

Documented certificate: A manufacturer-supplied, batch-specific Janoshik report, listed on our lab-reports page at /coa.
EU shipping: Shipped from within the EU customs territory; deliveries inside it generally avoid import clearance.
Fast delivery: Tracked delivery, typically a few business days; see the shipping page for current destination-specific estimates.

The current KLOW price is shown on the product page linked below.

Frequently Asked Questions